1201 Dual-Inhibition of RET and TrkA Pathways in Breast Cancer Brain Metastasis: A Pre-Clinical Study for Future Application of FDA-Approved RET and TrkA Inhibitors
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: Breast cancer brain metastasis (BCBM) remains a devastating disease due to limited actionable targets and lack of brain-permeable therapies. We previously reported that two receptor tyrosine kinases, RET and TrkA, are co-overexpressed and co-activated in BCBM and confer worse brain metastasis-free survival. While small molecule RET and Trk inhibitors have been FDA-approved for lung cancer showing ∼70% intracranial response rates, their utility individually or in combination for BCBM has not been evaluated. METHODS: We performed in vitro cell viability assays using human breast cancer brain tropic cell lines and various combinations of RET and TrkA inhibitors to evaluate for synergistic effects of combination vs. monotherapy. Cell lines were treated with combination and monotherapy and analyzed for the extent of apoptosis using Annexin V staining followed by flow cytometry. In vitro scratch wound assay was used to determine the effect of co-inhibition on cancer cell migratory capacity. Statistical analyses (t-test, ANOVA regression models, and Chou-Talalay method) were performed as appropriate. RESULTS: In vitro cell viability assays showed that RET and TrkA inhibitors synergized to reduce cell viability at multiple drug combination ratios (combination index < 1) in all three cell lines. Combination therapy was more effective at reducing cell viability than monotherapy (p < 0.01). Co-inhibition of RET and TrkA strongly induced apoptosis of brain tropic breast cancer cells in vitro compared to monotherapy (p < 0.01). Further, tumor cell migration was significantly inhibited independent of cell proliferation by the combination in comparison to monotherapy (p < 0.05). CONCLUSIONS: We provide novel evidence that co-inhibition of RET and TrkA is more effective than monotherapy in reducing cell viability and migratory capacity as well as inducing apoptosis in brain tropic breast cancer cells, thus supporting further BCBM studies using FDA-approved RET and TrkA inhibitors that have shown excellent cranial response rates in lung cancer patients with brain metastases.
Fields of Study & Subjects
Brain Metastases and Treatment
Cancer Mechanisms and Therapy
Lung Cancer Treatments and Mutations
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 234–235
- Publication date
- 26 March 2026
- Language
- EN